Literature DB >> 2575137

Evaluation of human and simian immunodeficiency virus plaque and neutralization assays.

J A McKeating1, A McKnight, K McIntosh, P R Clapham, C Mulder, R A Weiss.   

Abstract

A number of CD4+ T cell lines were compared for their ability to act as target cells for human immunodeficiency virus (HIV) infection in syncytium- and plaque-forming assays. MT-4 and C8166 cells were the most sensitive indicator cells for HIV- and simian immunodeficiency virus (SIV)-induced cytopathic effects, and gave rise to macroscopic (MT-4) and microscopic (C8166) plaques. The MT-4 plaque assay was evaluated for the measurement of HIV- and SIV-neutralizing antibodies.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2575137     DOI： 10.1099/0022-1317-70-12-3327

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  13 in total

1.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Authors:  J A McKeating; J Bennett; S Zolla-Pazner; M Schutten; S Ashelford; A L Brown; P Balfe
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

4.  Method for detection of simian immunodeficiency virus neutralizing antibodies using a noncommercial antigen capture enzyme-linked immunosorbent assay.

Authors:  M J Welch; M E Thouless
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

5.  Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay.

Authors:  B L Lohman; J Higgins; M L Marthas; P A Marx; N C Pedersen
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

6.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Authors:  J C Griffiths; E L Berrie; L N Holdsworth; J P Moore; S J Harris; J M Senior; S M Kingsman; A J Kingsman; S E Adams
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

Authors:  J McKeating; P Balfe; P Clapham; R A Weiss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Quantitation of human immunodeficiency virus type 1 infection kinetics.

Authors:  D S Dimitrov; R L Willey; H Sato; L J Chang; R Blumenthal; M A Martin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia.

Authors:  T F Schulz; D Whitby; J G Hoad; T Corrah; H Whittle; R A Weiss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.